Home › Encyclopedia › Efpeglenatide: Research Status And Trial Data
Research / Unapproved

Efpeglenatide: Research Status And Trial Data

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

Registered trials5

Key takeaways

  • Efpeglenatide is an investigational compound with no FDA-approved label or indication.
  • Five trials involving efpeglenatide are registered in the clinicaltrials.gov system.
  • Several late-stage trials compared efpeglenatide to existing diabetes therapies before being terminated.
  • No adverse event reporting data is currently available for this compound.

What efpeglenatide is

Efpeglenatide is a research compound that has not received approval from the FDA. No approved drug label, brand name, or confirmed mechanism of action is available in current regulatory records. Any use outside of registered clinical research is not supported by an approved indication.

Trial footprint

Five trials referencing efpeglenatide are registered in clinicaltrials.gov. The available sample includes phase 3 studies comparing efpeglenatide against dulaglutide and against placebo in people with type 2 diabetes whose condition was inadequately controlled with metformin, with basal insulin, or with combinations of oral antidiabetic drugs. The trials in this sample, including NCT03684642, NCT03713684, and NCT03770728, are all listed with a status of terminated. This status reflects study records as retrieved and does not by itself indicate the reason for termination or any conclusion about safety or efficacy.

FAQ

Is efpeglenatide FDA approved?
No. Efpeglenatide does not have an approved drug label from the FDA. It remains classified as an investigational compound based on currently available regulatory records.
What was efpeglenatide being studied for?
Available trial records show studies comparing efpeglenatide to dulaglutide and to placebo in people with type 2 diabetes not adequately controlled on other treatments. These were registered clinical research studies rather than approved uses.
Why were the efpeglenatide phase 3 trials terminated?
The trial records in this dataset list a status of terminated but do not include the underlying reason. Determining why a specific trial ended requires reviewing that trial's full registry record.
How many clinical trials have studied efpeglenatide?
Five trials referencing efpeglenatide are registered in clinicaltrials.gov as of the most recent data retrieval. A sample of three phase 3 trials from that group is described in available records.
Is there safety data available for efpeglenatide?
No adverse event report data is currently available for this compound in the reviewed sources. This means no summary of reported side effects can be provided at this time.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: ClinicalTrials.gov ChEMBL

Updated 2026-08-03